Pharmaceutical GnRH analogues temporarily suspend pituitary function thus preventing an undesired ovarian follicular rupture prior to egg collection. To achieve multiple ovarian follicular development, the doses of pituitary gonadotropins (Follicle-stimulating hormone, FSH/Luteinising hormone, LH) should be under total control better achieved when the pituitary gland will not produce these hormones on its own but with the help of medicinal GnRH Analogues.
They are separated in “agonists” marketed under the names Superfact, Daronda, Arvecap and “antagonists” under the names Orgalutran and Cetrotide. Their active ingredients are similar. They are marketed as nasal sprays or subcutaneous injections for daily administration or as 4-week slow-release injections. Depending on the pharmaceutical protocol, the type of GnRH analogue, administration method, and dosage will be selected.
